Protagonist Therapeutics Inc annual operating income for fiscal TTM was $59 million, compared with -$158 million in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| Operating Income (annual) | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (EBIT) | $59M | ($158M) | $253M | ($94M) | ($131M) | ($126M) | ($65M) | ($81M) | ($42M) | ($38M) | ($33M) | ($15M) | ($9M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Operating Income (quarterly) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Income (EBIT) | $159M | ($4M) | ($50M) | ($46M) | ($42M) | ($19M) | $127M | ($41M) | ($39M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More PTGX metrics: Revenue · Gross Profit · Net Income · EPS · EBITDA · Free Cash Flow · Shares Outstanding
All PTGX financial statements → Interactive PTGX charts →
About TickerBase · Data methodology & sources · Privacy · Terms